IBM News 6 October 2025 - 20 December 2025

February 6, 2026, 12:25 AM EST. MetLife's shares dropped 7.3% over the past year, closing at $75.32. Despite this, valuation models indicate potential undervaluation. An Excess Returns analysis estimates intrinsic value at $180.06 per share, suggesting the stock could be undervalued by 58.2%. This model compares MetLife's return on equity against its cost of equity, showing the insurer generates significant value above required return. Investors weigh its large U.S. insurance market position against sector risks like interest rate trends and capital requirements. The recent pullback may reflect broader industry concerns rather than company-specific issues. MetLife's 3-year and 5-year returns remain strong at 16.8% and 58.5%, respectively, despite short-term declines. Potential investors should watch sector dynamics carefully, considering multiple valuation approaches beyond share price alone.